A proteomics study in fibroblasts from FXTAS patients demonstrated the potential of SFN to regulate bioenergetics, UPR, proteasome, antioxidant, and iron metabolism pathways [285]. This evidence concerns the gene SFN and fragile X-associated tremor/ataxia syndrome.